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Combinatorial Drug Therapy with 
Phytochemicals as Adjuvants in 
Prostate Cancer Management
Rajalakshmi Manikkam and Indu Sabapathy
Abstract
Prostate cancer is one of the leading cancers in men needs a long period for 
development from small lesion to become a clinical manifestation. The prostate 
specific antigen is a prominent tumor marker for prostate cancer. Androgens are 
involved in the development and progression of prostate cancer regulating the 
androgen receptor as androgen-dependent or androgen-independent types. The 
latter occurs in metastatic conditions of prostate cancer developed as hormone 
resistant prostate cancer (HRPC) that inappropriately activates transcription of 
other genes involved in molecular pathways inducing cellular proliferation and 
inhibiting apoptosis. Since prostate cancer is characterized by slow growth and long 
latency period and thus integration of phytochemicals/compounds in combination 
with other existing therapies have promising future to manage cancer, thus control-
ling the disease progression and mortality rate. Therefore, the medicinal plants 
therapeutic or prophylactic activities on prostate cancer exhibiting anti-androgenic 
effects, depleting PSA, down-regulating expression of androgen receptor, regulat-
ing cell cycle regulators have promising future to be applied as adjuvant drugs in 
prostate cancer treatment.
Keywords: prostate cancer, androgen receptor, PSA, systemic therapy, 
phytochemicals, molecular pathways
1. Introduction
Statistical reports revealed that prostate cancer is the third leading cause of 
cancer deaths in men [1] causing the life of one in every 39 men in United States. 
Related to prostate cancer rates in India, the rates are more than 20 times higher in 
US whites, more than 10 times higher in US Asian Indians/Pakistanis, seven times 
higher among UK South Asians and twice as high among Singapore Indians [2]. 
Factors escalating the risk of prostate cancer include age above 50 years, cancer inci-
dence in family, ethnicity, modern diet, environmental factor, pollutants, etc. The 
role of inflammation in prostate diseases is suggested by the presence of inflam-
matory cells within the prostate of cancer patients [3]. The molecular mechanism 
responsible for inflammation mediated prostate cancer is not yet clear.
However, prostate cancer needs a long period for development from small lesion 
to become a clinical manifestation [4]. Tumor progression is revealed with compli-
cations in erectile dysfunction, skeletal bone pain, obstruction of lymph vessels, 
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and veins causing lower body edema. The development of high-grade prostatic 
intraepithelial neoplasia (HGPIN) is identified as an intermediate stage between 
benign epithelium and the invasive malignant carcinoma at the outset of prostate 
cancer. Four main patterns of high-grade PIN (HGPIN) have been described as 
tufting, micropapillary, cribriform, and flat [5].
Prostate specific antigen (PSA), major constituent in prostatic secretion and is 
used for screening prostatism. PSA testing is primarily associated with benign pros-
tatic hyperplasia (BPH), however there is only rare connectivity of patients having 
BPH to develop prostate cancer. With conditions like BPH, inflammation, and 
disruption of prostate basal membrane increases the permeability and releases PSA 
into the circulation. Prostate cancer antigen 3 (PCA3) is more specific than PSA 
which is an important biomarker in personalized medicine. Also analysis of urinary 
protein markers, such as TMPRSS2-ERG and PCA3 are helpful in early diagnosis 
of the disease. The other tumors markers reported as prostatic acid phosphatase 
(PAP), cytoskeletal proteins, and annexin I are downregulated in PIN whereas 
C-erbB-2 (HER-2/neu) and C-erbB-3 oncoproteins, c-met protooncogene, Bcl-2 
oncoprotein, several growth factors, nitric oxide synthase, alpha-methylacyl-CoA 
racemase, glycoprotein A-80, and apolipoprotein D, are upregulated in PIN. The 
histological grading system of prostate cancer is obtained from the Gleason score 
[6] which provides information that score 1–5 indicates low-grade prostate cancer 
and score 8–10 indicates high-grade prostate cancer. Digital rectal examination 
(DRE), examination of PSA levels, prostate ultrasound, and prostate biopsy are 
the current diagnostic methods in examining the primary and metastatic stages 
for prostate cancer [7, 8]. Prostate cancer stages are generally classified into three 
categories—T category, N category, and M category. T represents the primary 
tumor, N represents the cancer that has spread to regional (nearby) lymph nodes 
and M represents the distant metastasis cancer. The treatment strategies are admin-
istered based on the stage of cancer progression.
2. Androgen-dependent and androgen-independent prostate cancer
Human prostate is a walnut shaped, fibromuscular organ located beneath the 
urinary bladder and is made-up of several glandular and non-glandular components 
that are tightly fused together within a common capsule [9]. It is an exocrine gland 
functioning in secretion of complex proteolytic solution into the urethra during 
ejaculation which is important for sperm motility and nourishment. The growth 
and function of the prostate are regulated by androgens. The growth and develop-
ment of normal prostate requires functioning androgen signaling pathway, which 
is regulated by hypothalamic-pituitary gonadal axis. Androgens (includes testos-
terone and DHT) are responsible for the male secondary sexual characteristics. 
Testosterone is synthesized in the testes and released into the circulation in response 
to specific hormonal signals regulated by GnRH, FSH, and LH. Testosterone is 
transported by steroid hormone binding globulin (SHBG) to the prostate, where it 
is converted by 5α-reductase to its active metabolite 5α-dihydrotestosterone (DHT).
In the prostate, androgens mediate their effects via high affinity to the androgen 
receptor (AR), a nuclear transcription factor that controls expression of genes 
involved in growth, differentiation, homeostatsis, and apoptosis. Receptor for steroid 
and thyroid hormones are mostly cytoplasmic/nuclear receptors and hormone-
receptor complex binding to the promoter regions of responsive genes and stimulate 
or inhibit transcription from those genes. Nuclear receptors are ligand-inducible 
transcription factors that mediate the signals of a broad variety of fat-soluble hor-
mones, including the steroid and vitamin D3 hormones, thyroid hormones retinoids. 
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Upon ligand binding, AR translocates to the nucleus, binds to DNA recognition 
sequences, and activates transcription of genes involved in cell proliferation, 
apoptosis, and differentiation [10]. Androgens are involved in the development and 
progression of prostate cancer [11] regulating the AR. During this phase the tumors 
are referred to as androgen sensitive or dependent. The most common therapies done 
with prostate cancer patients are androgen deprivation therapy removing testicles 
partially or completely in addition to administration of drugs inhibiting LHRH secre-
tion and anti-androgen therapy blocking the androgen receptor interaction.
Prostate cancer can evolve into castration resistant cancers which is independent 
of androgen levels [12]. The AR signaling pathway continues to be active in hor-
mone resistant prostate cancer (HRPC) and can inappropriately activate tran-
scription [13]. Recent studies show that cancer progression and metastasis lead to 
alteration in the androgen receptor pathway genes with transition of prostate cancer 
from the androgen dependent to independent stage [14]. Mutations in the ligand-
binding domain alter the specificity of the AR enhancing the binding of estrogens, 
progesterone, and anti-androgens; and thereby decreasing its dependency on 
androgens while stimulating cell growth. In addition to AR mutations, a variety 
of growth factors, including insulin-like growth factor I, epidermal growth factor, 
and keratinocyte growth factor, can activate androgen-responsive genes via the AR, 
suggesting that androgen independence which occurs due to the over expression of 
growth factors in the local environment [15]. There are multiple evidences suggest-
ing that estrogens are involved in prostate carcinogenesis. In worldwide the African-
Americans have the higher risk of prostate cancer with elevated levels of serum 
estrone and estradiol levels even in healthy young men [16]. CCDC62/ERAP75 is a 
new co-activator of ER and this protein is mainly present in the nucleus and widely 
expressed in many prostate cancer cell lines (PC-3, DU145, LNCaP, 22Rv1) than in 
the normal prostate epithelial cells (BPH-1) [17].
3. Molecular regulations in prostate cancer
The inappropriate expression of the growth inhibitory factors appears to con-
tribute to prostate cancer progression. Epidermal growth factor (EGF) promotes 
chemo-migration of metastatic prostate cancer cells to lymph node and medullary 
bone sites [18]. In insulin signaling pathway, the ligand insulin binds to its recep-
tor followed by tyrosine phosphorylation of insulin receptor substrates (IRS) by 
the insulin receptor tyrosine kinase. Several studies suggested that alteration in 
the IGF signaling axis is associated with an increased risk of prostate cancer [19]. 
Signal transduction proteins interact with IRS including GRB2. GRB2 is a part of the 
cascade including SOS, RAS, RAF, and MEK that leads to activation of MAPK and 
mitogenic response in the form of gene transcription.
In AKT signaling pathway, PTEN is a regulator which is down regulated to pro-
tect the cell from tumor growth. The phosphatase activity on phosphatidylinositol 
3,4,5-triphosphate allows dephosphorylation of PIP3 to PIP2. The PIP2 inhibits the 
P13K which is the membrane bound domain. When the phosphatase activity is lost, 
P13K transfers its phosphate group to PDK1 and PDK2 which in turn causes phos-
phorylation of AKT protein and regulatory amino acids Ser473 and Thr308. This 
leads to activation of MDM2, P21, CASP9, mTOR genes leading to apoptosis inhibi-
tion, tumor growth, etc. Smad3 gene plays a key role in prostate cancer serving as an 
essential mediator of most Smad-dependent TGF-beta responses, including control 
of gene expression, cell growth, apoptosis, and tumor suppression. Deregulated/
enhanced expression and activation of AR in prostate carcinomas may intercept the 
tumor suppressor function of TGF-β through transcriptional suppression of Smad3.
Male Reproductive Health
4
TNFRs are activated by TNF in order to exhibit cellular response. TNF triggers the 
transcription of apoptotic proteins through NF-κB thereby achieving cell survival. 
Activation of TRAFs, such as TRAF2, TRAF5, and TRAF6 results in transduction of 
cellular response by TNFRs. In TNFRs pathway, TRAF3 acts as a repressor. APRL, 
BAFF, BAFF-R, BCMA, and TACI belong to the TNF superfamilies and play vital 
roles in immunity through B cells and T cells. BAFF binds to BAFF-R, BCMA, and 
TACI, while APRIL bands to two of them—BCMA and TACI only. In this pathway 
nuclear factors (NF-κB) are activated in signaling cascades. This activation process 
can be triggered by canonical and non-canonical pathways. The latter is activated by 
activation of BCMA, TCAI, and BAFF-R by BAFF. This counter activates TRAF2 and 
TRAF5 that signals NIK, a mitogen activated protein kinase. Once NIK is activated, 
phosphorylation of IKK-alpha that restrain processing NK-κB2 into NF-κB2 onsets. 
Along with RelB, NF-κB2 activates Bcl2 or Bcl-XL or both. Upon this activation cell 
survival is promoted. BAFF transcription is activated by NF-κB2 resulting in a posi-
tive feedback. I-kB is phosphorylated by IKK alpha, beta, and gamma which is acti-
vated by TRAF2 by canonical pathway. I-kB is disintegrated and ubiquitylated inside 
proteosome 26S. This process discharges NF-κB2 and RelA which are swiftly reposi-
tioned from cytoplasm to nucleus. Following which anti-apoptotic components, such 
as Bcl-2, Bcl-XL, and BFL1 are activated by transcription by NF-κB transfactors.
In non-canonical pathway, IKK alpha is activated by its phosphorylation once 
NIK kinase is promoted by TRAF. NF-κB2 is processed from p100 to p52 by IKK 
alpha which is adhered to RelB. The dimer (RelB-p52-NF-κB) engages in affecting 
gene transcription once it shifts to the nucleus. This pathway does not involve IKK 
beta and gamma. IKK, RelB, and NIK are mediated by TNF-R1 signal or TNF-R2 
signal as well. NF-κB promoted cell growth and proliferation in prostate cancer cells 
by regulating expression of genes, such as c-myc, cyclin D1, and IL-6. Furthermore, 
NF-κB-mediated expression of genes involved in angiogenesis (IL-8, VEGF), and 
invasion and metastasis (MMP 9, uPA, and uPA receptor) may further contribute to 
the progression of androgen depleted prostate cancer [20].
Apoptosis is programmed cell death involving sequential events of elimina-
tion of cells without releasing harmful substances into the surrounding area. 
Apoptosis plays a crucial role in developing and maintaining the health of the body 
by eliminating old cells, unnecessary cells, and unhealthy cells. The two classes of 
regulatory molecules play vital role in the cell cycle progression and apoptosis pro-
cesses are protein kinases, such as cyclin dependent kinases (CDKs), and cyclins. 
Disturbances in the cell cycle regulation due to uncontrolled cell growth and 
divisions through and escaping of the cell cycle checkpoints occur in the mutated 
cells. The cell cycle events are facilitated through the activated cyclin D-CDK4/6 
complexes phosphorylating the retinoblastoma protein (pRb) bound with E2F 
transcriptional factors. This in turn inactivates pRb and weakening its affinity for 
E2F which then becomes free to enter the nucleus and transcription of cell cycle 
progression genes. The hypophosphorylated pRb impounds the transcription factor 
E2F in the cytosol, thus blocking the cell cycle at G1 phase.
Similarly B-cell lymphoma (Bcl-2) family genes are involved in the apoptosis 
pathway, including prostate, breast, and ovarian cancers. The Bcl-2 family proteins 
had the anti-apoptotic subgroup, such as, Bcl-extra-large (Bcl-xL), Bcl2-like 2 
(Bcl-W), myeloid cell leukemia (Mcl-1) that interacted with another subgroup of 
proteins called the pro-apoptotic proteins (Bcl2-associated X protein (Bax) and 
Bcl2 antagonist/killer (Bak)). In the signal transduction cascade of apoptosis the 
pro-apoptotic proteins began induction of apoptosis via mitochondrial outer- 
membrane permeabilization, followed by the release of cytochrome c, and finally 
the activation of cysteine aspartyl proteases (caspases). Second is the intrinsic path-
way, with the release of cyt-c into the cytosol from mitochondria, a multiprotein 
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caspase-activating complex, called “apoptosome” binds procaspase-9 and cyt-c 
with its central component Apaf1, and activates apoptosis. Thus there should be 
a balance in the levels of anti-apoptotic and pro-apoptotic proteins for the proper 
progression of apoptosis (Figure 1).
4.  Phytomedicine: promoting synergistic actions in prostate cancer 
management
The history of ayurvedic and traditional systems of medicine showed that the 
medicinal plants have global importance in treating human diseases and disor-
ders [21]. The references of ancient literature, a Sumerian clay slab from Nagpur, 
approximately 5000 years old suggested that people were depended on drugs from 
the nature [22]. Theophrast (371-287 BC) in his scientific book titled “De Causis 
Plantarium” has referred and classified nearly 500 medicinal plants. About 700 plant 
species including pomegranate, castor oil plant, aloe, senna, garlic, onion, fig, wil-
low, coriander, juniper, common centaury, etc. [23] were reported having medicinal 
properties. The World Health Organization (WHO) estimated that trades of plant-
derived pharmaceutical drugs would account for five trillion US dollars by 2050.
The survey reports on these medicinally valued plants and their preparations 
as tinctures, teas, poultices, powders, and other herbal formulations [24] served as 
the basis for novel drug discovery wherein a large number of synthetic drugs are 
developed on the small-molecule natural chemical entities and has been introduced 
as potential drugs worldwide [25]. Even our natural food intake relays on the 
medicinal aspects followed in our tradition thus have a strong impact on determin-
ing health at different stages/phases of life. In addition many food-based nutrients 
contribute to the prevention and management of deadly diseases like cancer. 
Wholesome diet including vegetables, fruit, and vitamins lowers the risk up to 80% 
of cancers of the large bowel, breast, and prostate.
Figure 1. 
Molecular pathways involved in prostate cancer progression (developed by pathway construction tool—PathVisio).
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Based on the studies done at the US National Cancer Institute, selenium, vitamin 
E, and Omega-3 fatty acid have preventive roles in prostate carcinoma [26]. Plants 
produce a wide range of chemical compounds as by-products of their metabolic 
pathways known as secondary metabolites. These compounds have no direct role 
in growth yet they have significant role in defense mechanisms. The secondary 
metabolites generally flavonoids, tannins, curcumin, resveratrol, and gallocatechin 
are reported as effective anti-cancer drugs [27]. Molecular studies have proved that 
luteolin, quercetin, and kaempferol rich in onions, olives, grapes, tea, pomegranate, 
broccoli, and cauliflower [28] are effective in suppressing tumor development with 
low dose-limiting toxicities and negligible side effects [29].
Plants in nature contain many active compounds which elicit the synergistic 
effects in combination with chemical drugs through its own molecular mechanisms 
of targeting signaling pathways in cancer cells in order to overcome drug resistant 
cancers, also strengthens the therapeutic activity of chemical drugs and subsides 
drug-induced toxicity. The pharmacological efficacies of chemotherapeutic drugs 
are improvised by alteration in the pharmacokinetics of drug compounds regulating 
the receptor targets and downstream effector molecules in the cancer cells.
Sporadically, anti-androgens (anti-hormones) are administered for initial stages 
of prostate cancer which is prone to frequent failures in patients diagnosed with 
recurrent androgen-independent prostate cancer and metastasis. Radiotherapy 
and/or androgen deprivation therapy can be considered as an adjunct to surgery, in 
either the adjuvant or salvage setting, to further control the disease course. These 
combinatorial therapies are highly recommended in combating primary tumors, 
but metastatic tumors are more challenging due to loss of remedial activity and 
disease remission. Also these therapies are reported in exerting complications of 
damaging the normal cells in vicinity of tumor growth, disturbing the functioning 
of immune system, triggering autoimmunity [30], damage to adjacent gastro-
intestinal tract, and bladder incontinence. Hence, multifaceted therapies producing 
synergistic effects and long-term outcomes by lowering the local tumor burden and 
eradicating metastatic disease compared to each individual change are required for 
cancer management.
Prostate cancer is characterized by slow growth and long latency period and 
thus integration of phytochemicals/compounds in combination with other exist-
ing therapies have promising future to manage cancer, controlling the disease 
progression and mortality rate. The WHO has estimated that approximately 80% 
of the world’s population depends on traditional plant-based medicines for meet-
ing their primary health care needs [31]. In prostate cancer, there is an imbalance 
between prostate cell growth and apoptosis. In prostate cancer these proteins are 
over expressed which lead to progression of metastatic prostate cancer through 
inhibition of apoptotic cell death. This over expression also causes resistance to 
heat-shock stress, several chemotherapies, and radiotherapy. Phytochemicals are 
routinely used as an adjuvant to conventional chemo and radio therapies of cancer 
in order to manage the drug-resistance mechanisms and resensitize tumor cells.
Many medicinal plants are reported to possess chemopreventive activities on 
prostate cancer exhibiting significant oestrogenic and anti-androgen effects, such 
as Agathosma betulina [32], Bidens pilosa [33], Prunus Africana, Cucurbita pepo L. 
[34], Andrographis paniculata [35], Vaccinium macrocarpon [36], Linum persicum 
and Euphorbia cheradania [37], Panax ginseng [38], Scutellaria baicalensis [39], 
Wedelia chinensis [40], Urtica membranaceae, Artemisia monosperma and Origanum 
dayi [41], Vitis vinifera [42], an eight-herb Chinese formulation, that consists of 
Isatis indigotica, Glycyrrhiza glabra, Glycyrrhiza uralensis, Scutellaria baicalensis, 
Ganoderma lucidum, Panax ginseng, Dendranthema morifolium, Rabdosia rubescens 
[43]. Combined drugs made of vinca alkaloids, Taxus diterpenes, Podophyllum 
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lignans, and Camptotheca alkaloids were proved with anticancer effects [44]. 
Pentacyclic triterpenoids reported in Hypoxis hemerocallidea reduced the inflam-
mation and swelling in the prostate. Garlic and green tea catechins act as potential 
chemopreventive agents against cancer by inhibiting PIN [45]. Phytochemicals like 
geneistin and quercitin [46], lycopene [47], curcumin, epigallocatechin-gallate, 
resveratrol [48], brassinosteroid [49], derived from medicinal plants have been 
reported through in-vitro studies with potentials of anti-proliferative effects on 
prostate cancer cell lines, such as PC-3, DU-145, and LNCaP. Their protective action 
against cancer may be due to their high concentration of antioxidants that react 
with free radicals thereby neutralizing them [50].
Quercetin and curcumin, plant-derived flavanoids are well established drugs in 
cancer treatment exhibiting antioxidant, anti-inflammatory, and anti-proliferative 
activities [51]. Quercetin has anti-inflammatory role through regulation of NF-κB 
pathway genes [52] inhibiting the expression of pro-inflammatory cytokines, 
TNF-α, IL-6, and IL-1β and inflammatory mediators, nitric oxide, and catalase. 
Combination of quercetin with doxorubicin increases the sensitivity of PC3-
resistant cells by inducing apoptosis via reduction of mitochondrial membrane 
potential, activation of the PI3K/AKT pathway, and acceleration of chemo resis-
tance [53]. The chemopreventive and anti-neoplastic activity of the phytochemicals 
could be achieved through multiple effects including reduction of PSA and AR 
expression, induction of apoptotic pathways, inhibition of angiogenesis, induction 
of PKC-α, suppression of TrkE, induction of p53, inhibition of proteasome activity, 
induction of S-phase and G0/G1 phase and G2/M cell-cycle arrest, suppression of 
DNA synthesis, up-regulation of protein expression WAF1/p21, KIP1/p27, INK4a/
p16, INK4c/p18, down-regulation of protein expression cyclin D1 and D3, cyclin E, 
cdk2, cdk4, cdk6, inhibition of PI3K/PKB phosphorylation of AKT, Inhibition of 
COX-2 expression [54]. Wedelia chinensis extract possesses the ability in reducing 
the gene expressions of proinflammatory cytokines and STAT3 activity in tumor-
elicited myeloid cells [40]. Altogether, the combination of herbal compounds 
includes pharmacokinetic and pharmacodynamic synergisms to provide significant 
therapeutic effects. Baicalein form Scutellaria baicalensis [39] reduces the synthesis 
of eicosanoid that function as important mediators in inflammatory responses 
through inhibiting enzymatic oxidation of essential fatty acids.
One of our studies reported that, a potential medicinal herb Gymnema sylvestre has 
been proved for its potency to control prostate cancer progression [55]. It is (family: 
Asclepiadaceae) described as miracle fruit, is native to central and western India that 
has been used in the traditional health care system, for several centuries [56]. The 
leaves are rich in triterpene classes of oleanane saponins (gymnemic acids and gymne-
masaponins) and dammarene saponins (gymnemasides). The phytocompound dihy-
droxy gymnemic triacetate (DGT) isolated from acetone extract of G. sylvestre leaves 
were effective in inhibiting prostate cancer cell growth, inducing apoptosis, modula-
tion of cell cycle, and downregulation of the protein expressions. Also the depletion 
of PSA observed in the PC-3 cell line caused by DGT was observed. Since PSA gene 
is positively regulated via binding of AR to the androgen responsive elements in the 
promoter of PSA, decline of PSA levels proves down-regulation of AR [57].
5. Conclusion
Thus multimodal approach of treating prostate cancer with the integration of 
phytochemicals as chemopreventive agents in down-regulation of cell proliferation 
and induction of apoptosis has taken forefront in development of potential thera-
peutic drugs in cancer management.
Male Reproductive Health
8
Author details
Rajalakshmi Manikkam* and Indu Sabapathy
Department of Biotechnology and Bioinformatics, Holy Cross College 
(Autonomous), Tamil Nadu, India
*Address all correspondence to: mdraji@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
9Combinatorial Drug Therapy with Phytochemicals as Adjuvants in Prostate Cancer Management
DOI: http://dx.doi.org/10.5772/intechopen.86157
References
[1] Torre LA, Bray F, Siegel RL, Ferlay J, 
Lortet-Tieulent J, Jemal A. Global cancer 
statistics, 2012. CA: A Cancer Journal 
for Clinicians. 2015;65:87-108
[2] Rastogi T, Devesa S, Mangtani P, 
Mathew A, Cooper N, Kao R, et al. 
Cancer incidence rates among south 
Asians in four geographic regions: India, 
Singapore, UK and US. International 
Journal of Epidemiology. 
2008;37:147-160
[3] Novara G, Galfano A, Berto RB, 
Ficarra V, Navarrete RV, Artibani 
W. Inflammation, apoptosis, and 
BPH: What is the evidence. European 
Association of Urology. 2006;5:401-409
[4] Griffiths K, Prezioso D, Turkes A, 
Denis LJ. The prevention of prostate 
cancer. Recent Results in Cancer 
Research. 2007;175:33-63
[5] Bostwick DG. High-grade prostatic 
intraepithelial neoplasia: The most likely 
precursor of prostate cancer. Cancer. 
1995;75:1823-1836
[6] Humphrey PA. Gleason grading 
and prognostic factors in carcinoma 
of the prostate. Modern Pathology. 
2004;17:292-306
[7] Heidenreich A, Bellmunt J, Bolla M, 
Joniau S, Mason M, Matveev V, et al. 
EAU guidelines on prostate cancer. Part 
I: Screening, diagnosis, and treatment 
of clinically localised disease. European 
Urology. 2011;59:61-71
[8] Kabalin JN, Hodge KK, McNeal JE, 
Freiha FS, Stamey TA. Identification of 
residual cancer in the prostate following 
radiation therapy: Role of transrectal 
ultrasound guided biopsy and prostate 
specific antigen. The Journal of Urology. 
1989;142:326-331
[9] Mc Neal JE. The prostate gland: 
Morphology and pathophysiology. 
Monograph Urology. 1983;4:3-12
[10] Lonergan PE, Tindall DJ. Androgen 
receptor signaling in prostate cancer 
development and progression. Journal 
of Carcinogen. 2011;10:20
[11] Ross RK, Bernstein L, Judd H, 
Hanisch R, Pike M, Henderson B. Serum 
testosterone levels in healthy young 
black and white men. Journal of the 
National Cancer Institute. 1986;76:45-48
[12] Quayle SN, Mawji NR, Wang J, 
Sadar MD. Androgen receptor decoy 
molecules block the growth of prostate 
cancer. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2007;104:1331-1336
[13] Kasper S, Cookson MS. Mechanisms 
leading to the development of 
hormone-resistant prostate cancer. The 
Urologic Clinics of North America. 
2006;33:201-210
[14] Edwards J, Bartlett JM. The 
androgen receptor and signal 
transduction pathways in hormone-
refractory prostate cancer. Part 2: 
Androgen-receptor cofactors and 
bypass pathways. BJU International. 
2005;95:1327-1335
[15] Culig Z, Hobisch A, Cronauer MV, 
Radmayr C, Trapman J, Hittmair A, 
et al. Androgen receptor activation in 
prostatic tumor cell lines by insulin-like 
growth factor-I, keratinocyte growth 
factor and epidermal growth factor. 
Cancer Research. 1994;54:5474-5478
[16] Srinivasan SR, Freedman DS, 
Sundaram GS, Webber LS, Berenson 
GS. Racial (black-white) comparisons 
of the relationship of levels of 
endogenous sex hormones to serum 
lipoproteins during male adolescence, 
the Bogalusa heart study. Circulation. 
1986;74:1226-1232
[17] Chen M, Ni J, Chang HC, Lin CY, 
Muyan M, Yeh S. CCDC62/ERAP75 
functions as a coactivator to enhance 
Male Reproductive Health
10
estrogen receptor beta-mediated 
transactivation and target gene 
expression in prostate cancer cells. 
Carcinogenesis. 2009;30:841-850
[18] Rajah R, Vanderslice R, Kapur 
S, Lynch J, Thompson R, Djakjew 
D. Epidermal growth factor (EGF) 
promotes chemomigration of a human 
prostate tumor cell line and EGF 
immunoreactive proteins are present 
at sites of metastasis in the stroma of 
lymph nodes and medullary bone. The 
Prostate. 1996;28:1-9
[19] Chokkalingam A, Pollak M, 
Fillmore C, Gao Y, Stanczyk F, Deng 
J, et al. Insulin-like growth factors 
and prostate cancer: A population 
based case-control study in China. 
Cancer Epidemiology, Biomarkers & 
Prevention. 2001;10:421-427
[20] Suh J, Rabson AB. NF-kappaB 
activation in human prostate cancer: 
Important mediator or epiphenomenon? 
Journal of Cellular Biochemistry. 
2004;91:100-117
[21] Platel K, Srinivasan K. Plant foods 
in the management of diabetes mellitus: 
Vegetables as potential hypoglycaemic 
agents. Die Nahrung. 1997;41:68-74
[22] Stojanoski N. Development of 
health culture in Veles and its region 
from the past to the end of the 20th 
century. Veles: Society of Science and 
Art. 1999:13-34
[23] Glesinger L. Medicine through 
Centuries. Zagreb: Zora; 1954. pp. 21-38
[24] Samuelsson G. Drugs of Natural 
Origin: A Textbook of Pharmacognosy. 
Stockholm: 5th Swedish Pharmaceutical 
Press; 2004
[25] Newman DJ, Cragg GM. Natural 
products as sources of new drugs over 
the last 25 years. Journal of Natural 
Products. 2007;70:461-477
[26] Lippman SM, Goodman PJ, 
Klein EA, Parnes HL, Thompson 
IM Jr, Kristal AR, et al. Designing 
the selenium and vitamin E cancer 
prevention trial (SELECT). Journal 
of the National Cancer Institute. 
2005;97:94-102
[27] Azmi AS, Bhat SH, Hanif S, Hadi 
SM. Plant polyphenols mobilize 
endogenous copper in human peripheral 
lymphocytes leading to oxidative DNA 
breakage: A putative mechanism for 
anticancer properties. FEBS Letters. 
2006;580:533-538
[28] Kozlowska A, Szostak-Wegierek 
D. Flavonoids—Food sources and 
health benefits. Roczniki Państwowego 
Zakładu Higieny. 2014;65:79-85
[29] Kallifatidis G, Hoy JJ, Lokeshwar 
BL. Bioactive natural products for 
chemoprevention and treatment 
of castration-resistant prostate 
cancer. Seminars in Cancer Biology. 
2016;40-41:160-169
[30] James N. Primer on Prostate Cancer. 
London, UK: Springer Healthcare Ltd; 
2014
[31] Biswa K, Chattopadhyay I, Banerjee 
RK, Bandopadhyay U. Biological 
activities and medicinal properties of 
neem (Azadirachta indica). Current 
Science. 2002;82:1336-1345
[32] Watt JM, Breyer-Brandwijk MG. 
The Medicinal and Poisonous Plants 
of Southern and Eastern Africa: Being 
an Account of their Medicinal and 
Other Uses, Chemical Composition, 
Pharmacological Effects and Toxicology 
in Man and Animal. 2nd ed. Teviot 
Place, Edinburgh: E. & S. Livingstone 
Ltd.; 1962:16-17
[33] Hutchings A, Scott AH, Lewis 
G, Cunningham A. Zulu, Medicinal 
Plants: An Inventory. Pietermaritzburg: 
University of Natal Press; 1996
11
Combinatorial Drug Therapy with Phytochemicals as Adjuvants in Prostate Cancer Management
DOI: http://dx.doi.org/10.5772/intechopen.86157
[34] Steenkamp V. Phytomedicines 
for the prostate. Fitoterapia. 
2003;74:545-552
[35] Kumar RA, Sridevi K, Kumar NV, 
Nanduri S, Rajagopal S. Anticancer 
and immunostimulatory compounds 
from Andrographis paniculata. 
Journal of Ethnopharmacology. 
2004;92(2-3):291-295
[36] Neto CC. Cranberry and its 
phytochemicals: A review of in vitro 
anticancer studies. The Journal of 
Nutrition. 2007;137:186S
[37] Raffo AJ, Perlman H, Chen MW, 
Day ML, Streitman JS, Buttyan R. 
Overexpression of bcl-2 protects 
prostate cancer cells from apoptosis 
in vitro and confers resistance to 
androgen depletion in vivo. Cancer 
Research. 1995;55:4438-4445
[38] Wang W, Zhao Y, Rayburn ER, 
Hill DL, Wang H. Zhang, in vitro 
anti cancer and structure activity 
relationships of natural products 
isolated from fruits of Panax 
ginseng. Cancer Chemotherapy and 
Pharmacology. 2007;59(55):89-601
[39] Chen S, Ruan Q , Bedner E, et al. 
Effects of the flavonoid baicalin and 
its metabolite baicalein on androgen 
receptor expression, cell cycle progression 
and apoptosis of prostate cancer cell lines. 
Cell Proliferation. 2001;34:293-304
[40] Lin FM, Chen LR, Lin EH, et al. 
Compounds from Wedelia chinensis 
synergistically suppress androgen 
activity and growth in prostate cancer 
cells. Carcinogenesis. 2007;28:2521-2529
[41] Solowey E, Lichtenstein M, Sallo S, 
Paavilainen H, Solowet E, Lorberboum-
Galski H. Evaluating medicinal plants 
for anticancer activity. The Scientific 
World Journal. 2014:1-12
[42] Stagos D, Amoutzias GD, Matakos 
A, Spyrou A, Tsatsakis AM, Kouretas 
D. Chemoprevention of liver cancer by 
plant polyphenols. Food and Chemical 
Toxicology. 2012;50:2155-2170
[43] Small EJ, Frohlich MW, Bok R, 
Shinohara K, Grossfeld G, Rozenblat 
Z, et al. Prospective trial of the herbal 
supplement PC-SPES in patients with 
progressive prostate cancer. Journal of 
Clinical Oncology. 2000;18:3595-3603
[44] Khazir J, Mir BA, Pilcher L, Riley 
DL. Role of plants in anticancer drug 
discovery. Phytochemistry Letters. 
2014;7:173-181
[45] Arunkumar A, Vijayababu MR, 
Venkataraman P, Senthilkumar K, 
Arunakaran J. Chemoprevention of 
rat prostate carcinogenesis by diallyl 
disulfide, an organosulfur compound 
of garlic. Biological & Pharmaceutical 
Bulletin. 2006;29:375-379
[46] Phillip CJ, Christopher K, Giardina 
CK, Bilir B, Cutler DJ, Lai YH, et al. 
Genistein cooperates with the histone 
deacetylase inhibitor vorinostat to 
induce cell death in prostate cancer cells. 
BMC Cancer. 2012;12:145
[47] Von Low EC, Perabo FG, Siener 
R, Muller SC. Facts and fiction of 
phytotherapy for prostate cancer: A 
critical assessment of preclinical and 
clinical data. In Vivo. 2007;21:189-204
[48] Ratan HL, Steward WP, Gescher 
AJ, Mellon JK. Resveratrol—A prostate 
cancer chemopreventive agent. Urologic 
Oncology. 2002;7:223-227
[49] Cimino S, Sortino G, Favilla 
V, Castelli T, Madonia MS, Russo 
GI, et al. Polyphenols: Key issues 
involved in chemoprevention 
of prostate cancer. Oxidative 
Medicine and Cellular Longevity; 
2012;2012:632959
[50] Malíková J, Swaczynová J, 
Kolář Z, Strnad M. Anticancer and 
antiproliferative activity of natural 
Male Reproductive Health
12
brasinosteroids. Phtyochemistry. 
2008;69:418-426
[51] Bischoff SC. Quercetin: Potentials in 
the prevention and therapy of disease. 
Current Opinion in Clinical Nutrition 
and Metabolic Care. 2008;11:733-740
[52] Li Y, Yao J, Han C, Yang J, Chaudhry 
MT, Wang S, et al. Quercetin, 
inflammation and immunity. Nutrients. 
2016;8:167
[53] Tang KD, Ling MT. Targeting drug-
resistant prostate cancer with dual PI3K/
mTOR inhibition. Current Medicinal 
Chemistry. 2014;21:3048-3056
[54] Ravindran J, Prasad S, Aggarwa 
BB. Curcumin and cancer cells: How 
many ways can curry kill tumor 
cells selectively? The AAPS Journal. 
2009;11:495-510
[55] Nivedha RP, Venkatesan S, Singh 
SK, Selvaraj C, Rajalakshmi M. 
Chemopreventive effect of saponin 
isolated from Gymnema sylevestre on 
prostate cancer through in silico and 
in vivo analysis. Medicinal Chemistry 
Research. 2017;26:1915-1925
[56] Porchezhian E, Dobriyal RM. An 
overview on the advances of Gymnema 
sylvestre: Chemistry. pharmacology and 
patents. Pharmazie. 2003;58:5-12
[57] Mostaghel EA, Page ST, Lin DW, 
et al. Intraprostatic androgens and 
androgen-regulated gene expression 
persist after testosterone suppression: 
Therapeutic implications for castration-
resistant prostate cancer. Cancer 
Research. 2007;67:5033-5041
